Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: High yield production of the biologically active recombinant plectasin peptide

OMICS A Journal of Integrative Biology

Volumn 17, Issue 11, 2013, Pages 560-567

  Rothan, Hussin A ^a   Mohamed, Zulqarnain ^b   Suhaeb, Abdulrazzaq M ^c   Rahman, Noorsaadah Abd ^a   Yusof, Rohana ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Mushroom Research Centre   (Malaysia)

^c Department of Paediatrics   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 10A; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PLECTASIN; RECOMBINANT PLECTASIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL CELL; CELL INCLUSION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERO CELL; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIVIRAL AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; ESCHERICHIA COLI; FACTOR XA; INCLUSION BODIES; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; STAPHYLOCOCCUS AUREUS; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84887028599     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2013.0056     Document Type: Article

References (35)

1. Botting C, and Kuhn RJ. (2012). Novel approaches to flavivirus drug discovery. Expert Opin Drug Discov 7, 417-428.
2. Brinch KS, Frimodt-Moller N, Hoiby N, and Kristensen HH. (2009). Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics. Antimicrob Agents Chemother 53, 4794-4800.
3. Erbel P, Schiering N, D'Arcy A, et al. (2006). Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13, 372-373. (Pubitemid 43873510)
4. Ganesh VK, Muller N, Judge K, et al. (2005). Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem 13, 257-264. (Pubitemid 39575709)
5. Geiss BJ, Stahla H, Hannah AM, Gari AM, and Keenan SM. (2009). Focus on flaviviruses: Current and future drug targets. Future Med Chem 1, 327-344.
6. Gubler DJ. (2002). Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10, 100-103. (Pubitemid 34119347)
7. Hara S, Mukae H, Sakamoto N, et al. (2008). Plectasin has antibacterial activity and no effect on cell viability or IL-8 production. Biochem Biophys Res Commun 374, 709-713.
8. Hazrati E, Galen B, Lu W, et al. (2006). Human alpha-and betadefensins block multiple steps in herpes simplex virus infection. J Immunol 177, 8658-8666. (Pubitemid 44893830)
9. Holowachuk EW, and Ruhoff MS. (1995). Efficient gene synthesis by Klenow assembly/extension-Pfupolymerase amplification (KAPPA) of overlapping oligonucleotides. Genome Res 4, 299-302.
10. Hotez PJ. (2011). New antipoverty drugs, vaccines, and diagnostics: A research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis 5, e1133.
11. Jing XL, Luo XG, Tian WJ, et al. (2010). High-level expression of the antimicrobial peptide plectasin in Escherichia coli. Curr Microbiol 61, 197-202.
12. Knox JE, Ma NL, Yin Z, et al. (2006). Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J Med Chem 49, 6585-6590. (Pubitemid 44657452)
13. Liang QL, Zhou K, and He HX. (2010). Retrocyclin 2: A new therapy against avian influenza H5N1 virus in vivo and vitro. Biotechnol Lett 32, 387-392.
14. Mandal K, Pentelute BL, Tereshko V, et al. (2009). Racemic crystallography of synthetic protein enantiomers used to determine the X-ray structure of plectasin by direct methods. Protein Sci 18, 1146-1154.
15. Mao R, Teng D, Wang X, et al. (2013). Design, expression, and characterization of a novel targeted plectasin against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol 97, 3991-4002.
16. Modis Y, Ogata S, Clements D, and Harrison SC. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100, 6986-6991. (Pubitemid 36706380)
17. Modis Y, Ogata S, Clements D, and Harrison SC. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319. (Pubitemid 38133652)
18. Monath TP. (1994). Dengue: The risk to developed and developing countries. Proc Natl Acad Sci USA 91, 2395-2400. (Pubitemid 24139356)
19. Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, et al. (2008). Identification and biochemical characterization of small molecule inhibitors of West Nile virus serine protease by a high throughput screen. Antimicrob Agents Chemother 52, 3385-3393.
20. Muhammad Azami NA, Salleh SA, Neoh HM, Syed Zakaria SZ, and Jamal R. (2011). Dengue epidemic in Malaysia: Not a predominantly urban disease anymore. BMC Res Notes 4, 216.
21. Munk C, Wei G, Yang OO, et al. (2003). The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retrovir 19, 875-881. (Pubitemid 37338913)
22. Mygind PH, Fischer RL, Schnorr KM, et al. (2005). Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975-980. (Pubitemid 41486973)
23. Owen SM, Rudolph DL, Wang W, et al. (2004). RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retrovir 20, 1157-1165. (Pubitemid 39557866)
24. Rothan HA, Abdulrahman AY, Sasikumer PG, et al. (2012a). Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J Biomed Biotechnol 2012, 251482.
25. Rothan HA, Han HC, Ramasamy TS, et al. (2012b). Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis 12, 314.
26. Schmitz J, and Holzgrabe U. (2010). [Plectasin-a new peptide antibiotic with high therapeutic potential]. Pharm Unserer Zeit 39, 336-338.
27. Schneider T, Kruse T, Wimmer R, et al. (2010). Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328, 1168-1172.
28. Sijwali PS, Brinen L, and Rosenthal PJ. (2001). Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. Protein Expression Purif 22, 128-134. (Pubitemid 32548229)
29. Stadler K, Allison SL, Schalich J, and Heinz FX. (1997). Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71: 8475-8481. (Pubitemid 27446428)
30. Stoermer MJ, Chappell KJ, Liebscher S, et al. (2008). Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem 51, 5714-5721.
31. Tomlinson SM, Malmstrom RD, and Watowich SJ. (2009). New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets 9, 327-343.
32. Yasin B, Wang W, Pang M, et al. (2004). Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 78, 5147-5156. (Pubitemid 38581467)
33. Yon C, Teramoto T, Mueller N, et al. (2005). Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. J Biol Chem 280: 27412-27419. (Pubitemid 41040783)
34. Yusof R Clum S, Wetzel M, Murthy HM, and Padmanabhan R. (2000). Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 275: 9963-9969. (Pubitemid 30202042)
35. Zhang J, Yang Y, Teng D, Tian Z, Wang S, and Wang J. (2011). Expression of plectasin in Pichia pastoris and its characterization as a new antimicrobial peptide against Staphyloccocus and Streptococcus. Protein Expr Purif 78, 189-196.